Innovative Industrial Properties Reports Fourth Quarter and Full Year 2025 Results
Raised
Executed leases for 337,000 square feet in Q4'25 and Q1'26 To Date
Executive Chairman Remarks
“During 2025, we made significant progress executing on our strategy to diversify the Company’s portfolio, strengthen our balance sheet, and actively resolve tenant-related matters," said
Full Year 2025 Highlights
-
Total revenues of
$266.0 million and net income attributable to common stockholders of$114.4 million , or$3.93 per diluted share (all per share amounts in this press release are reported on a diluted basis unless otherwise noted). -
Adjusted funds from operations ("AFFO") of
$205.4 million , or$7.24 per diluted share. -
Declared dividends to common stockholders totaling
$7.60 per share, increasing IIP’s common stock dividends declared each year since its inception in 2016. Since its inception, IIP has paid over$1.1 billion in common stock dividends to its stockholders. -
In August, announced a strategic and diversifying investment of up to
$270.0 million inIQHQ, Inc. , a premier life science real estate platform ("IQHQ"), including a fully funded$100.0 million revolving credit facility and$170.0 million of preferred equity, of which$50.0 million had been funded as of year end. - Signed new leases comprising 339,000 square feet and totaling 4% of the total portfolio’s rentable square feet.
-
Issued 1,016,852 shares of Series A Preferred Stock under IIP's "at-the-market" equity offering program ("ATM Program") for
$24.1 million in net proceeds. -
Closed on a new three-year,
$100.0 million secured revolving credit facility with a federally regulated commercial bank that bears interest at one-month SOFR + 200 basis points.
|
|
Year Ended |
|
Year Ended |
||||||||
|
|
|
|
|
||||||||
|
(in thousands, except per share amounts) |
Amount |
|
Per Share |
|
Amount |
|
Per Share |
||||
|
Net income attributable to common stockholders |
$ |
114,435 |
|
$ |
3.93 |
|
$ |
159,857 |
|
$ |
5.52 |
|
Normalized FFO |
|
193,522 |
|
|
6.82 |
|
|
237,071 |
|
|
8.31 |
|
AFFO |
|
205,412 |
|
|
7.24 |
|
|
256,144 |
|
|
8.98 |
| ___________________________________________________ |
|
Definitions of the above-mentioned non-GAAP financial measures, together with reconciliations to net income in accordance with GAAP and other definitions of capitalized terms used herein, appear at the end of this release. |
Fourth Quarter 2025 and Recent Highlights
Financial Results and Dividend
-
Total revenues of
$66.7 million and net income attributable to common stockholders of$30.7 million , or$1.06 per share. -
AFFO of
$53.3 million , or$1.88 per share. -
Paid a quarterly dividend of
$1.90 per common share onJanuary 15, 2026 to stockholders of record as ofDecember 31, 2025 .
|
|
Three Months Ended
|
|
Three Months Ended
|
||||||||
|
|
|
||||||||||
|
(in thousands, except per share amounts) |
Amount |
|
Per Share |
|
Amount |
|
Per Share |
||||
|
Net income attributable to common stockholders |
$ |
30,705 |
|
$ |
1.06 |
|
$ |
39,461 |
|
$ |
1.36 |
|
Normalized FFO |
|
50,377 |
|
|
1.78 |
|
|
58,567 |
|
|
2.05 |
|
AFFO |
|
53,333 |
|
|
1.88 |
|
|
63,361 |
|
|
2.22 |
| ___________________________________________________ |
|
Definitions of the above-mentioned non-GAAP financial measures, together with reconciliations to net income in accordance with GAAP and other definitions of capitalized terms used herein, appear at the end of this release. |
-
As of
December 31, 2025 , the Company had funded an aggregate of$150.0 million of its strategic investment inIQHQ, Inc. , consisting of a fully funded$100.0 million revolving credit facility and$50.0 million of Series G preferred equity. The Company remains committed to funding up to an additional$120.0 million of preferred equity, in multiple tranches between the second quarter of 2026 and the second quarter of 2027.
Portfolio - Leasing
-
In
November 2025 , executed a 70,000 square foot full-building lease for IIP’sNorth Palm Springs, California property to a privateCalifornia operator. -
In
November 2025 , executed a 58,000 square foot full-building lease for IIP’sHolliston, Massachusetts property to Perpetual Brands, a privateMassachusetts operator. -
In
January 2026 , executed a 204,000 square foot full-building lease for IIP'sDesert Hot Springs, California property to Gramlin, a privateCalifornia operator.
Portfolio - Tenant Updates
- The following table summarizes payments received from certain defaulted tenants during the periods presented and the corresponding per share impact (in thousands, except per share amounts):
|
|
|
Three Months Ended
|
|
Three Months Ended
|
|
Q1'26 To Date |
||||||||||||
|
|
|
|
|
|||||||||||||||
|
Tenant |
|
Total Payments |
Per Share(1) |
|
Total Payments |
Per Share(1) |
|
Total Payments |
Per Share(1) |
|||||||||
|
Gold Flora |
|
$ |
820 |
$ |
0.03 |
|
$ |
3,738 |
$ |
0.13 |
|
$ |
1,500 |
$ |
0.05 |
|||
|
|
|
|
252 |
|
0.01 |
|
|
242 |
|
0.01 |
|
|
1,454 |
|
0.05 |
|||
|
Total |
|
$ |
1,072 |
$ |
0.04 |
|
$ |
3,980 |
$ |
0.14 |
|
$ |
2,954 |
$ |
0.10 |
|||
| _______________________________________________ | ||
|
(1) |
For the three months ended |
|
-
PharmaCann -
In December, the Company regained possession of its 66,000 square foot cultivation property in
Illinois and subsequently signed an LOI with a new tenant in January. -
In
January 2026 , theOhio court released$1.3 million , or$0.05 per share, to the Company comprised of the rent payments previously required to be escrowed with the court byPharmaCann for the time period from July throughDecember 2025 . -
The Company is actively working to regain possession of its remaining cultivation properties in
Pennsylvania ,Ohio andNew York .
-
In December, the Company regained possession of its 66,000 square foot cultivation property in
-
Gold Flora
-
During the fourth quarter of 2025, the Company received
$3.7 million , or$0.13 per share, to be applied toward the unpaid rent due during the receivership. -
During the first quarter of 2026, the Company has received an additional
$1.5 million , or$0.05 per share, in settlement of all remaining unpaid administrative rents due from the receivership.
-
During the fourth quarter of 2025, the Company received
-
4Front
-
The Company has an executed LOI for its 250,000 cultivation property in
Illinois with a new tenant. -
The Company agreed to terms with a tenant for its 67,000 square foot property in
Georgetown, MA , subject to the close out of certain contingencies relating to the receivership sale. -
The Company agreed to terms with a tenant for its 114,000 square foot property in
Olympia, WA , subject to the close out of certain contingencies relating to the receivership sale. -
The Company agreed to terms with a tenant for its 57,000 square foot property in
Holliston, MA , subject to the close out of certain contingencies relating to the receivership sale.
-
The Company has an executed LOI for its 250,000 cultivation property in
Balance Sheet Highlights (at
-
14% debt to total gross assets, with
$2.7 billion in total gross assets. -
Total liquidity was
$107.6 million , consisting of cash and cash equivalents (as reported in IIP’s consolidated balance sheet as ofDecember 31, 2025 ) and availability under IIP’s revolving credit facility. - Debt service coverage ratio of 10.4x (calculated in accordance with IIP’s 5.50% Unsecured Senior Notes due 2026).
Financing Activity
-
Preferred Stock
-
During the quarter ended
December 31, 2025 , the Company issued 211,843 shares its of 9.00% Series A Preferred Stock under its ATM Program for$5.0 million in net proceeds. -
Subsequent to
December 31, 2025 , the Company issued an additional 1,794,323 shares of its 9.00% Series A Preferred Stock under its ATM Program for$40.4 million in net proceeds. -
In total, the Company has raised
$45.4 million in net proceeds from preferred stock issuances since the beginning of the fourth quarter of 2025.
-
During the quarter ended
-
New Revolving Credit Facility
-
In October, closed on a new three-year,
$100.0 million secured revolving credit facility (the “Life Science Credit Facility”) with a federally regulated commercial bank. The Life Science Credit Facility is secured by the Company’s IQHQ investment and had an interest rate of 6.1% as ofDecember 31, 2025 . The Life Science Credit Facility also includes a$35.0 million “accordion feature” that permits the Company to expand the borrowing capacity to a total of$135.0 million , subject to the addition of other lenders. As ofDecember 31, 2025 , outstanding borrowings under our Life Science Credit Facility were$75.0 million .
-
In October, closed on a new three-year,
Financial Results
For the three months ended
For the three months ended
For the three months ended
Dividend
On
Supplemental Information
Supplemental financial information is available in the Investor Relations section of IIP’s website at www.innovativeindustrialproperties.com.
Teleconference and Webcast
About
This press release contains statements that IIP believes to be “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than historical facts are forward-looking statements. When used in this press release, words such as IIP “expects,” “intends,” “plans,” “estimates,” “anticipates,” “believes” or “should” or the negative thereof or similar terminology are generally intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding potential transactions, including properties subject to letters of intent or other non-binding agreements, the consummation of which remains subject to the negotiation and execution of definitive documentation, satisfaction of customary closing conditions and other contingencies, including those relating to receivership sale processes. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. You should not rely on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and which could materially affect actual results, performances or achievements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risk factors discussed in the Company's most recent Annual Report on Form 10-K for the year ended
|
CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except share and per share amounts)
|
|||||||
|
Assets |
|
|
|
||||
|
Real estate, at cost: |
|
|
|
||||
|
Land |
$ |
146,320 |
|
|
$ |
146,772 |
|
|
Buildings and improvements |
|
2,269,597 |
|
|
|
2,230,807 |
|
|
Construction in progress |
|
40,593 |
|
|
|
62,393 |
|
|
Total real estate, at cost |
|
2,456,510 |
|
|
|
2,439,972 |
|
|
Less accumulated depreciation |
|
(343,062 |
) |
|
|
(271,190 |
) |
|
Net real estate held for investment |
|
2,113,448 |
|
|
|
2,168,782 |
|
|
Life science investments |
|
152,665 |
|
|
|
— |
|
|
Construction loan receivable |
|
22,800 |
|
|
|
22,800 |
|
|
Cash and cash equivalents |
|
47,597 |
|
|
|
146,245 |
|
|
Investments |
|
— |
|
|
|
5,000 |
|
|
Right of use office lease asset |
|
509 |
|
|
|
946 |
|
|
In-place lease intangible assets, net |
|
6,366 |
|
|
|
7,385 |
|
|
Other assets, net |
|
27,473 |
|
|
|
26,889 |
|
|
Total assets |
$ |
2,370,858 |
|
|
$ |
2,378,047 |
|
|
|
|
|
|
||||
|
Liabilities and stockholders’ equity |
|
|
|
||||
|
Liabilities: |
|
|
|
||||
|
Notes due 2026, net |
$ |
290,602 |
|
|
$ |
297,865 |
|
|
Revolving credit facilities |
|
102,500 |
|
|
|
— |
|
|
Building improvements and construction funding payable |
|
2,964 |
|
|
|
10,230 |
|
|
Accounts payable and accrued expenses |
|
10,870 |
|
|
|
10,561 |
|
|
Dividends payable |
|
54,913 |
|
|
|
54,817 |
|
|
Rent received in advance and tenant security deposits |
|
50,307 |
|
|
|
57,176 |
|
|
Other liabilities |
|
10,698 |
|
|
|
11,338 |
|
|
Total liabilities |
|
522,854 |
|
|
|
441,987 |
|
|
|
|
|
|
||||
|
Stockholders’ equity: |
|
|
|
||||
|
Preferred stock, par value |
|
47,780 |
|
|
|
23,632 |
|
|
Common stock, par value |
|
28 |
|
|
|
28 |
|
|
Additional paid-in capital |
|
2,113,184 |
|
|
|
2,124,113 |
|
|
Dividends in excess of earnings |
|
(312,988 |
) |
|
|
(211,713 |
) |
|
Total stockholders’ equity |
|
1,848,004 |
|
|
|
1,936,060 |
|
|
Total liabilities and stockholders’ equity |
$ |
2,370,858 |
|
|
$ |
2,378,047 |
|
|
CONSOLIDATED STATEMENTS OF INCOME
For the Three Months and Years Ended (Unaudited) (In thousands, except share and per share amounts)
|
||||||||||||||||
|
|
|
For the Three Months Ended
|
|
For the Years Ended
|
||||||||||||
|
|
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|
Revenues: |
|
|
|
|
|
|
|
|
||||||||
|
Rental (including tenant reimbursements) |
|
$ |
66,631 |
|
|
$ |
76,717 |
|
|
$ |
265,486 |
|
|
$ |
306,936 |
|
|
Other |
|
|
26 |
|
|
|
27 |
|
|
|
469 |
|
|
|
1,581 |
|
|
Total revenues |
|
|
66,657 |
|
|
|
76,744 |
|
|
|
265,955 |
|
|
|
308,517 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Expenses: |
|
|
|
|
|
|
|
|
||||||||
|
Property expenses |
|
|
7,980 |
|
|
|
7,605 |
|
|
|
30,177 |
|
|
|
28,472 |
|
|
General and administrative expense |
|
|
7,967 |
|
|
|
8,891 |
|
|
|
33,735 |
|
|
|
37,444 |
|
|
Depreciation and amortization expense |
|
|
18,538 |
|
|
|
18,240 |
|
|
|
74,068 |
|
|
|
70,807 |
|
|
Impairment loss on real estate |
|
|
— |
|
|
|
— |
|
|
|
3,527 |
|
|
|
— |
|
|
Total expenses |
|
|
34,485 |
|
|
|
34,736 |
|
|
|
141,507 |
|
|
|
136,723 |
|
|
Gain (loss) on sale of real estate |
|
|
(326 |
) |
|
|
— |
|
|
|
(326 |
) |
|
|
(3,449 |
) |
|
Income from operations |
|
|
31,846 |
|
|
|
42,008 |
|
|
|
124,122 |
|
|
|
168,345 |
|
|
Interest and other income |
|
|
6,721 |
|
|
|
2,553 |
|
|
|
14,320 |
|
|
|
10,988 |
|
|
Interest expense |
|
|
(6,726 |
) |
|
|
(4,536 |
) |
|
|
(20,195 |
) |
|
|
(17,672 |
) |
|
Net income |
|
|
31,841 |
|
|
|
40,025 |
|
|
|
118,247 |
|
|
|
161,661 |
|
|
Preferred stock dividends |
|
|
(1,136 |
) |
|
|
(564 |
) |
|
|
(3,812 |
) |
|
|
(1,804 |
) |
|
Net income attributable to common stockholders |
|
$ |
30,705 |
|
|
$ |
39,461 |
|
|
$ |
114,435 |
|
|
$ |
159,857 |
|
|
Net income attributable to common stockholders per share: |
|
|
|
|
|
|
|
|
||||||||
|
Basic |
|
$ |
1.07 |
|
|
$ |
1.38 |
|
|
$ |
3.98 |
|
|
$ |
5.58 |
|
|
Diluted |
|
$ |
1.06 |
|
|
$ |
1.36 |
|
|
$ |
3.93 |
|
|
$ |
5.52 |
|
|
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
|
||||||||
|
Basic |
|
|
27,913,384 |
|
|
|
28,254,565 |
|
|
|
28,005,228 |
|
|
|
28,226,402 |
|
|
Diluted |
|
|
28,303,530 |
|
|
|
28,554,335 |
|
|
|
28,377,227 |
|
|
|
28,530,650 |
|
|
FFO, NORMALIZED FFO AND AFFO
For the Three Months and Years Ended (Unaudited) (In thousands, except share and per share amounts)
|
|||||||||||||||
|
|
|
For the Three Months Ended
|
|
For the Years Ended
|
|||||||||||
|
|
|
|
2025 |
|
|
|
2024 |
|
|
2025 |
|
|
|
2024 |
|
|
Net income attributable to common stockholders |
|
$ |
30,705 |
|
|
$ |
39,461 |
|
$ |
114,435 |
|
|
$ |
159,857 |
|
|
Real estate depreciation and amortization |
|
|
18,538 |
|
|
|
18,240 |
|
|
74,068 |
|
|
|
70,807 |
|
|
Impairment loss on real estate |
|
|
— |
|
|
|
— |
|
|
3,527 |
|
|
|
— |
|
|
Loss on sale of real estate/(Disposition-contingent lease termination fee, net of loss on sale of real estate)(1) |
|
|
326 |
|
|
|
— |
|
|
326 |
|
|
|
(451 |
) |
|
FFO attributable to common stockholders (basic) |
|
|
49,569 |
|
|
|
57,701 |
|
|
192,356 |
|
|
|
230,213 |
|
|
Cash and non-cash interest expense on Exchangeable Senior Notes |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
28 |
|
|
FFO attributable to common stockholders (diluted) |
|
|
49,569 |
|
|
|
57,701 |
|
|
192,356 |
|
|
|
230,241 |
|
|
Litigation-related expense |
|
|
585 |
|
|
|
268 |
|
|
2,008 |
|
|
|
788 |
|
|
Loss (gain) on partial repayment of Notes due 2026 |
|
|
— |
|
|
|
— |
|
|
(32 |
) |
|
|
— |
|
|
Income on seller-financed notes(2) |
|
|
223 |
|
|
|
30 |
|
|
(835 |
) |
|
|
1,104 |
|
|
Deferred lease payments received on sales-type leases(3) |
|
|
— |
|
|
|
568 |
|
|
25 |
|
|
|
4,938 |
|
|
Normalized FFO attributable to common stockholders (diluted) |
|
|
50,377 |
|
|
|
58,567 |
|
|
193,522 |
|
|
|
237,071 |
|
|
Stock-based compensation |
|
|
2,698 |
|
|
|
4,315 |
|
|
10,132 |
|
|
|
17,317 |
|
|
Non-cash interest expense |
|
|
568 |
|
|
|
456 |
|
|
1,999 |
|
|
|
1,664 |
|
|
Non-cash accretion of life science investments |
|
|
(333 |
) |
|
|
— |
|
|
(333 |
) |
|
|
— |
|
|
Above-market lease amortization |
|
|
23 |
|
|
|
23 |
|
|
92 |
|
|
|
92 |
|
|
AFFO attributable to common stockholders (diluted) |
|
$ |
53,333 |
|
|
$ |
63,361 |
|
$ |
205,412 |
|
|
$ |
256,144 |
|
|
FFO per common share – diluted |
|
$ |
1.75 |
|
|
$ |
2.02 |
|
$ |
6.78 |
|
|
$ |
8.07 |
|
|
Normalized FFO per common share – diluted |
|
$ |
1.78 |
|
|
$ |
2.05 |
|
$ |
6.82 |
|
|
$ |
8.31 |
|
|
AFFO per common share – diluted |
|
$ |
1.88 |
|
|
$ |
2.22 |
|
$ |
7.24 |
|
|
$ |
8.98 |
|
|
Weighted average common shares outstanding – basic |
|
|
27,913,384 |
|
|
|
28,254,565 |
|
|
28,005,228 |
|
|
|
28,226,402 |
|
|
Restricted stock and RSUs |
|
|
390,146 |
|
|
|
299,770 |
|
|
371,999 |
|
|
|
294,780 |
|
|
Dilutive effect of Exchangeable Senior Notes |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
9,468 |
|
|
Weighted average common shares outstanding – diluted |
|
|
28,303,530 |
|
|
28,554,335 |
|
28,377,227 |
|
|
28,530,650 |
|
|||
| __________________________________________________ | ||
|
(1) |
For the year ended |
|
|
(2) |
Positive amounts represent non-refundable cash payments received pursuant to two seller-financed notes issued by us in connection with our disposition of certain properties. As the transactions did not qualify for recognition as completed sales under GAAP, the payments were initially recorded as a deposit liability and included in other liabilities on our consolidated balance sheet. For the year ended |
|
|
(3) |
Amount reflects the non-refundable lease payments received on two sales-type leases which are recognized as a deposit liability starting on |
|
Non-GAAP Financial Measures
Funds From Operations (FFO)
FFO and FFO per share are operating performance measures adopted by the
Management believes that net income, as defined by GAAP, is the most appropriate earnings measurement. However, management believes FFO and FFO per share to be supplemental measures of a REIT’s performance because they provide an understanding of the operating performance of IIP's properties without giving effect to certain significant non-cash items, primarily depreciation expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. IIP believes that by excluding the effect of depreciation, FFO and FFO per share can facilitate comparisons of operating performance between periods. IIP reports FFO and FFO per share because these measures are observed by management to also be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs and because FFO per share is consistently reported, discussed, and compared by research analysts in their notes and publications about REITs. For these reasons, management has deemed it appropriate to disclose and discuss FFO and FFO per share.
Normalized Funds from Operations (Normalized FFO)
IIP computes Normalized FFO by adjusting FFO, as defined by NAREIT, to exclude certain GAAP income and expense amounts that management believes are infrequent and unusual in nature and/or not related to IIP's core real estate operations. Exclusion of these items from similar FFO-type metrics is common within the equity REIT industry, and management believes that presentation of Normalized FFO and Normalized FFO per share provides investors with a metric to assist in their evaluation of IIP's operating performance across multiple periods and in comparison to the operating performance of other companies, because it removes the effect of unusual items that are not expected to impact IIP's operating performance on an ongoing basis. Normalized FFO is used by management in evaluating the performance of IIP's core business operations.
During the year ended
Adjusted Funds from Operations (AFFO)
Management believes that AFFO and AFFO per share are also appropriate supplemental measures of a REIT’s operating performance. IIP calculates AFFO by adjusting Normalized FFO for certain non-cash items.
For the year ended
IIP’s computation of FFO, Normalized FFO and AFFO may differ from the methodology for calculating FFO, Normalized FFO and AFFO utilized by other equity REITs and, accordingly, may not be comparable to such REITs. Further, FFO, Normalized FFO and AFFO do not represent cash flow available for management’s discretionary use. FFO, Normalized FFO and AFFO should not be considered as an alternative to net income (computed in accordance with GAAP) as an indicator of IIP’s financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of IIP’s liquidity, nor is it indicative of funds available to fund IIP’s cash needs, including IIP’s ability to pay dividends or make distributions. FFO, Normalized FFO and AFFO should be considered only as supplements to net income computed in accordance with GAAP as measures of IIP’s operations.
Definitions
Debt: Calculated as the sum of the carrying value of the Notes due 2026 and the Revolving Credit Facilities, as presented on IIP's consolidated balance sheet as of
Gross Assets: Calculated as total assets plus accumulated depreciation, as presented on IIP's consolidated balance sheet as of
View source version on businesswire.com: https://www.businesswire.com/news/home/20260223001239/en/
Company Contact:
Chief Financial Officer
(858) 997-3332
Source:
